Skip to main content
. 2022 Jan 25;10(2):261. doi: 10.3390/biomedicines10020261

Figure 3.

Figure 3

Overview of biologicals (anti-IL1β, anti-PDL-1) and small molecules such as RTK-inhibitors (RKI) for targeting NF-κB-signaling in cancer and CSCs.